3d
GlobalData on MSNTakeda broadens its deal with BridGene for up to $770mBridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...
BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Takeda.
BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...
Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in ...
BridGene is also eligible to receive tiered royalties on net sales of any products that may result from the collaboration. "We are excited to continue our collaboration with Takeda in the ...
Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results